VIB Signs Cooperation Agreement For The Development Of A New, Universal Flu Vaccine

This week the Flanders Interuniversity Institute for Biotechnology (VIB) has entered into an agreement with the British company Acambis for the development of a new flu vaccine. Together VIB and Acambis want to develop a universal flu vaccine that offers protection from all flu variants. Furthermore this vaccine will not need to be renewed annually. VIB researchers linked to the Ghent University - led by Walter Fiers, professor Molecular Biology and former director of one of the Ghent VIB departments - carried out the research on which this new flu vaccine is based.

MORE ON THIS TOPIC